Entropy Technologies LP Has $6.37 Million Position in Boston Scientific Corporation $BSX

Entropy Technologies LP cut its position in Boston Scientific Corporation (NYSE:BSX) by 21.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 65,283 shares of the medical equipment provider’s stock after selling 17,530 shares during the period. Entropy Technologies LP’s holdings in Boston Scientific were worth $6,374,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BSX. Steph & Co. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. bought a new position in Boston Scientific during the third quarter worth about $25,000. Murphy & Mullick Capital Management Corp grew its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter valued at about $26,000. Finally, United Community Bank increased its holdings in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup lowered its price target for BSX from $102 to $94 but kept a Buy rating, which still implies significant upside from current levels and signals some analyst confidence in the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks published a market‑move note explaining the stock’s drop today, providing context on trading and investor reaction rather than new company fundamentals. Why Boston Scientific (BSX) Dipped
• Neutral Sentiment: Multiple law firms are circulating investor notices and deadline reminders (lead‑plaintiff motions due May 4, 2026). These solicitations increase headline volume and may drive short‑term selling even before any case merits are resolved. Example notices: Pomerantz and Robbins Geller. Pomerantz Investor Alert Robbins Geller Notice
• Negative Sentiment: A filed securities class action alleges executives misrepresented U.S. electrophysiology procedure volumes — if these allegations gain traction they could lead to regulatory scrutiny, litigation costs or reputational damage. Lawsuit Allegations
• Negative Sentiment: Unusually heavy put‑option buying has been reported, suggesting some traders are positioning for further near‑term downside or hedging against headline risk. That activity can amplify intraday declines. Put Options Activity

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.5%

Shares of Boston Scientific stock opened at $68.62 on Friday. The firm has a market cap of $101.82 billion, a PE ratio of 35.37, a P/E/G ratio of 0.97 and a beta of 0.69. The business’s 50 day simple moving average is $82.98 and its 200 day simple moving average is $93.64. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a 52-week low of $67.56 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. JPMorgan Chase & Co. cut their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Wells Fargo & Company lowered their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Evercore dropped their target price on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Morgan Stanley cut their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, TD Cowen reduced their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $108.00.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.